ArticleAnnals of surgical oncology2010
Outcome of patients with a positive sentinel lymph node who do not undergo completion lymphadenectomy.
Article in Annals of surgical oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.
- Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2012Guideline
- Article
- Recent Evolution in the Management of Lymph Node Metastases in Melanoma.Kansas journal of medicine · 2021Article
- The prognostic significance of non-sentinel lymph node metastasis in cutaneous and acral melanoma patients-A multicenter retrospective study.Cancer communications (London, England) · 2020Article
- Evolving management of positive regional lymph nodes in melanoma: Past, present and future directions.Oncology reviews · 2019Article
- Completion lymphadenectomy for sentinel node positive cutaneous head & neck melanoma.Laryngoscope investigative otolaryngology · 2018Article
- Updates on the clinical diagnosis and management of ocular sebaceous carcinoma: a brief review of the literature.OncoTargets and therapy · 2018Review
- Improvement and persistent disparities in completion lymph node dissection: Lessons from the National Cancer Database.Journal of surgical oncology · 2017Article
- Impact of Completion Lymph Node Dissection on Patients with Positive Sentinel Lymph Node Biopsy in Melanoma.Journal of the American College of Surgeons · 2016Article
- Melanoma metastasis: new concepts and evolving paradigms.Oncogene · 2014Review
- Sentinel lymph node biopsy in melanoma: our 8-year clinical experience in a single French institute (2002-2009).BMC dermatology · 2012Article
- Surgical treatment of melanoma patients with early sentinel node involvement.Current treatment options in oncology · 2012Review
- Decoding melanoma metastasis.Cancers · 2010Article
- Why does no one want to perform lymph node dissection anymore?Annals of surgical oncology · 2010Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
backgroundCompletion lymph node dissection (CLND), although considered a standard approach for patients with melanoma and a positive sentinel lymph node (SLN), is not performed in as many as 50% of indicated cases. This study evaluates the outcome of patients who had a positive SLN but did not undergo CLND at Memorial Sloan-Kettering Cancer Center.
methodsA prospective database was used to identify all patients with a positive SLN from 1992 to 2008. Patient and tumor characteristics, number of positive SLNs, recurrence pattern, reason for not performing a CLND, and current status were evaluated.
resultsThere were 2269 patients who underwent SLN biopsy. Three hundred thirteen had a positive SLN, of whom 271 (87%) had a CLND and 42 (13%) did not. Patients in the no-CLND group were older (median age 70 vs. 56 years, P < .01), and had a trend toward thicker melanomas (3.5 vs. 2.8 mm, P < .06). A significantly higher percentage of no- CLND patients had lower-extremity melanomas (40% vs. 13% CLND; P < .01). The most common reason for not performing a CLND was patient refusal (45%). There were similar rates and patterns of recurrence between the two groups. Recurrence-free survival and disease-specific survival were also similar between the groups.
conclusionsIt remains unclear whether CLND must be performed in all melanoma patients with a positive SLN. For selected informed patients who choose not to participate in the Multicenter Selective Lymphadenectomy Trial II trial, or in centers where the trial is not available, nodal observation may be an acceptable option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.